Market Access News | pharmaphorum

News

Digital health tech for back pain recommended for NHS use

Seven digital health technologies that could help millions of people with lower back pain have been recommended for NHS in draft guidance published by cost-effectiveness o

News

Alnylam’s expansion plan for Onpattro blocked by FDA

Alnylam has abandoned plans to add cardiomyopathy to the label for transthyretin-mediated amyloidosis (ATTR) therapy Onpattro after the FDA turned down its marketing appli

News

Scotland first in Europe to back MSD drug for VHL tumours

Scotland has become the first country in Europe to recommend coverage of MSD’s Welireg as a treatment for some people with von Hippel-Lindau disease (VHL), a rare genetic

News

GSK to lean on Zhifei for Shingrix and maybe Arexvy in China

GSK is enlisting the aid of China’s Chongqing Zhifei Biological Products (Zhifei) to drive sales of its most important vaccine, Shingrix, in China over the next few years,

News

FDA panel sceptical on Lumakras confirmatory data

An FDA advisory committee has voted that Amgen’s confirmatory phase 3 trial for KRAS inhibitor Lumakras is not enough to support full approval, but it seems unlikely that

News

Novavax gets green light for updated COVID vaccine

Novavax has been given the go-ahead by regulators in the US for an updated version of its COVID-19 vaccine that targets the XBB.1.5 variant of the coronavirus.

Digital health tech for back pain recommended for NHS use

Alnylam’s expansion plan for Onpattro blocked by FDA

Scotland first in Europe to back MSD drug for VHL tumours

GSK to lean on Zhifei for Shingrix and maybe Arexvy in China

FDA panel sceptical on Lumakras confirmatory data

Novavax gets green light for updated COVID vaccine

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks